BACKGROUND: The interrelationship of left ventricular hypertrophy (LVH) with ejection fraction (EF) and their impact on mortality in non-dialysis-dependent chronic kidney disease (NDD-CKD) is unclear. METHODS: We examined the associations of EF and LVH with all-cause mortality in a historic cohort of 650 male US veterans with moderate-to-advanced NDD-CKD. EF and LVH were examined both separately and after categorizing patients according to their concomitant EF and presence/absence of LVH. Associations with mortality were examined in Cox models with adjustments for demographics, blood pressure, comorbidities, smoking status, medication use and biochemical characteristics. RESULTS: EF <30 and 30-50% were associated with higher all-cause mortality compared to EF >50% even after multivariable adjustments [multivariable adjusted hazard ratio, 95% confidence interval (CI): 2.83 (1.86-4.30) and 1.38 (1.06-1.78), P < 0.001 for linear trend]. LVH in itself was not associated with mortality [multivariable adjusted hazard ratio, 95% CI: 0.83 (0.66-1.05), P = 0.12], but the presence of LVH combined with an EF <50% was associated with the highest mortality [multivariable adjusted hazard ratios, 95% CI in patients with EF >50% + LVH, EF ≤ 50%-LVH and EF ≤ 50% + LVH, compared to EF >50%-LVH: 0.84 (0.63-1.13), 1.36 (1.00-1.83) and 1.62 (1.07-2.46)]. CONCLUSIONS: Low EF is associated with higher mortality in patients with NDD-CKD. In the presence of a low EF, LVH is also associated with higher mortality. Clinical trials are needed to determine if interventions targeting patients with low EF and LVH can lower mortality in NDD-CKD.
BACKGROUND: The interrelationship of left ventricular hypertrophy (LVH) with ejection fraction (EF) and their impact on mortality in non-dialysis-dependent chronic kidney disease (NDD-CKD) is unclear. METHODS: We examined the associations of EF and LVH with all-cause mortality in a historic cohort of 650 male US veterans with moderate-to-advanced NDD-CKD. EF and LVH were examined both separately and after categorizing patients according to their concomitant EF and presence/absence of LVH. Associations with mortality were examined in Cox models with adjustments for demographics, blood pressure, comorbidities, smoking status, medication use and biochemical characteristics. RESULTS: EF <30 and 30-50% were associated with higher all-cause mortality compared to EF >50% even after multivariable adjustments [multivariable adjusted hazard ratio, 95% confidence interval (CI): 2.83 (1.86-4.30) and 1.38 (1.06-1.78), P < 0.001 for linear trend]. LVH in itself was not associated with mortality [multivariable adjusted hazard ratio, 95% CI: 0.83 (0.66-1.05), P = 0.12], but the presence of LVH combined with an EF <50% was associated with the highest mortality [multivariable adjusted hazard ratios, 95% CI in patients with EF >50% + LVH, EF ≤ 50%-LVH and EF ≤ 50% + LVH, compared to EF >50%-LVH: 0.84 (0.63-1.13), 1.36 (1.00-1.83) and 1.62 (1.07-2.46)]. CONCLUSIONS: Low EF is associated with higher mortality in patients with NDD-CKD. In the presence of a low EF, LVH is also associated with higher mortality. Clinical trials are needed to determine if interventions targeting patients with low EF and LVH can lower mortality in NDD-CKD.
Authors: M A Quinones; A D Waggoner; L A Reduto; J G Nelson; J B Young; W L Winters; L G Ribeiro; R R Miller Journal: Circulation Date: 1981-10 Impact factor: 29.690
Authors: I W Hammond; R B Devereux; M H Alderman; E M Lutas; M C Spitzer; J S Crowley; J H Laragh Journal: J Am Coll Cardiol Date: 1986-03 Impact factor: 24.094
Authors: Mirela Dobre; Jason Roy; Kaixiang Tao; Amanda H Anderson; Nisha Bansal; Jing Chen; Rajat Deo; Paul Drawz; Harold I Feldman; L Lee Hamm; Thomas Hostetter; John W Kusek; Claudia Lora; Akinlolu O Ojo; Kumar Shrama; Mahboob Rahman Journal: Am J Nephrol Date: 2016-05-28 Impact factor: 3.754
Authors: Lekha K George; Santhosh K G Koshy; Miklos Z Molnar; Fridtjof Thomas; Jun L Lu; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: Circ Heart Fail Date: 2017-08 Impact factor: 8.790
Authors: Rathika Krishnasamy; Nicole M Isbel; Carmel M Hawley; Elaine M Pascoe; Matthew Burrage; Rodel Leano; Brian A Haluska; Thomas H Marwick; Tony Stanton Journal: PLoS One Date: 2015-05-15 Impact factor: 3.240
Authors: Robert Claus; Dominik Berliner; Udo Bavendiek; Nicolas Vodovar; Ralf Lichtinghagen; Sascha David; Margret Patecki; Jean-Marie Launay; Johann Bauersachs; Hermann Haller; Marcus Hiss; Michael S Balzer Journal: Clin Res Cardiol Date: 2020-01-30 Impact factor: 5.460
Authors: Janna Terhuerne; Merel van Diepen; Rafael Kramann; Johanna Erpenbeck; Friedo Dekker; Nikolaus Marx; Jürgen Floege; Michael Becker; Georg Schlieper Journal: Clin Kidney J Date: 2021-01-19